Clinical Trial

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT07266493
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Enrollment 26 participants
Start Date 2023-12-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-05